Skip to main navigation Skip to search Skip to main content

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

  • Robert J. Kreitman
  • , Claire Dearden
  • , Pier Luigi Zinzani
  • , Julio Delgado
  • , Lionel Karlin
  • , Tadeusz Robak
  • , Douglas E. Gladstone
  • , Philipp le Coutre
  • , Sascha Dietrich
  • , Mirjana Gotic
  • , Loree Larratt
  • , Fritz Offner
  • , Gary Schiller
  • , Ronan Swords
  • , Larry Bacon
  • , Monica Bocchia
  • , Krimo Bouabdallah
  • , Dimitri A. Breems
  • , Agostino Cortelezzi
  • , Shira Dinner
  • Michael Doubek, Bjorn Tore Gjertsen, Marco Gobbi, Andrzej Hellmann, Stephane Lepretre, Frederic Maloisel, Farhad Ravandi, Philippe Rousselot, Mathias Rummel, Tanya Siddiqi, Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham Wilson, Ira Pastan, Nai Shun Yao, Francis Giles
  • National Cancer Institute (NCI)
  • The Royal Marsden NHS Foundation Trust
  • University of Bologna
  • Hospital Clínic
  • Centre Hospitalier Lyon-Sud
  • Medical University of Lodz
  • Johns Hopkins Oncology Center
  • Charité – Universitätsmedizin Berlin
  • Ruprecht-Karls-University Heidelberg
  • Clinical Center of Serbia
  • University of Alberta
  • Ghent University Hospital
  • McGill University
  • Sylvester Comprehensive Cancer Center
  • St James's Hospital
  • Azienda Ospedaliera Universitaria Senese
  • Bordeaux University Hospital
  • Ziekenhuis Netwerk Antwerp
  • University of Milan
  • Northwestern University Feinberg School of Medicine
  • Masaryk University
  • Haukeland University Hospital
  • IRCCS for Oncology and Neurosciences
  • Medical University of Gdańsk
  • Centre Henri Becquerel
  • SOL Hematology
  • Department of Cancer Biology
  • Centre Hospitalier de Versailles
  • Université Paris-Saclay
  • Justus-Liebig-University
  • City of Hope National Med Center
  • Bnai Zion Medical Center
  • L’hôpital Côte de Nacre
  • University of New Mexico
  • University of Turin
  • New York-Presbyterian Hospital/Weill-Cornell Medical Center
  • MedImmune LLC
  • MedImmune, Inc.
  • Developmental Therapeutics LLC

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

237 Citations (Scopus)

Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Original languageEnglish
Pages (from-to)1768-1777
Number of pages10
JournalLeukemia
Volume32
Issue number8
DOIs
Publication statusPublished - 1 Aug 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia'. Together they form a unique fingerprint.

Cite this